References

Unresolved reference

2026 · External reference

Is disease stability an attainable chronic obstructive pulmonary disease treatment goal?

10.1164/rccm.202406-1254ci · 2025 · External reference

Prognostic risk factors for moderate-to-severe exacerbations in patients with chronic obstructive pulmonary disease: a systematic literature review

10.1186/s12931-022-02123-53 · 2022 · External reference

Susceptibility to exacerbation in chronic obstructive pulmonary disease

10.1056/nejmoa0909883 · 2010 · External reference

Exacerbation history and blood eosinophil count prior to diagnosis of COPD and risk of subsequent exacerbations

10.1183/13993003.02240-2023 · 2024 · External reference

Risk of death and cardiovascular events following an exacerbation of COPD: the EXACOS-CV US study

10.2147/copd.s438893 · 2024 · External reference

The sustained increase of cardiovascular risk following COPD exacerbations: meta-analyses of the EXACOS-CV studies

10.1183/23120541.01091-2024 · 2025 · External reference

An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal

10.1164/rccm.202108-1819pp · 2021 · External reference

Association between Rome classification among hospitalized patients with COPD exacerbations and short-term and intermediate-term outcomes

10.1016/j.chest.2023.07.021 · 2023 · External reference

Validation study of Rome criteria for assessing COPD exacerbation severity and predicting clinical outcomes: Turkish Thoracic Society COPD Assembly

10.2147/copd.s554744 · 2025 · External reference

Multidi­mensional prognostic risk stratification of COPD exacerbations: the ­baseline, acuity, and trigger (BAt) model

10.1016/s2213-2600(25)00362-5 · 2026 · External reference

Prompt initiation of triple therapy following hospitalization for a chronic obstructive pulmonary disease exacerbation in the United States: an analysis of the PRIMUS study

10.18553/jmcp.2022.28.12.1366 · 2022 · External reference

Benefit of prompt initiation of single-inhaler fluticasone furoate, umeclidinium, and vilanterol (FF/UMEC/VI) in patients with COPD in England following an exacerbation: a retrospective cohort study

10.1186/s12931-023-02523-1 · 2023 · External reference

Dupilumab for COPD with type 2 inflammation indicated by eosinophil counts

10.1056/nejmoa2303951 · 2023 · External reference

Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation

10.1056/nejmoa2401304 · 2024 · External reference

Mepolizumab for eosinophilic chronic obstructive pulmonary disease

10.1056/nejmoa1708208 · 2017 · External reference

Mepolizumab to prevent exacerbations of COPD with an eosinophilic phenotype

10.1056/nejmoa2413181 · 2025 · External reference